KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2016 - 2017)

Supernus Pharmaceuticals (SUPN) has disclosed Current Deferred Revenue for 7 consecutive years, with $287000.0 as the latest value for Q4 2017.

  • On a quarterly basis, Current Deferred Revenue rose 37.32% to $287000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $287000.0, a 37.32% increase, with the full-year FY2017 number at $287000.0, up 37.32% from a year prior.
  • Current Deferred Revenue was $287000.0 for Q4 2017 at Supernus Pharmaceuticals, roughly flat from $287000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $417000.0 in Q1 2013 to a low of $143000.0 in Q2 2014.
  • A 5-year average of $218350.0 and a median of $207500.0 in 2016 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 79.74% in 2013; the steepest drop was 59.84% in 2013.
  • Supernus Pharmaceuticals' Current Deferred Revenue stood at $204000.0 in 2013, then dropped by 29.9% to $143000.0 in 2014, then increased by 23.08% to $176000.0 in 2015, then rose by 18.75% to $209000.0 in 2016, then skyrocketed by 37.32% to $287000.0 in 2017.
  • Per Business Quant, the three most recent readings for SUPN's Current Deferred Revenue are $287000.0 (Q4 2017), $287000.0 (Q3 2017), and $287000.0 (Q2 2017).